533 related articles for article (PubMed ID: 26525985)
1. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
[TBL] [Abstract][Full Text] [Related]
2. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden.
Thorstenson A; Bratt O; Akre O; Hellborg H; Holmberg L; Lambe M; Bill-Axelson A; Stattin P; Adolfsson J
Eur J Cancer; 2012 Jul; 48(11):1672-81. PubMed ID: 22386317
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
4. Fracture risk in Danish men with prostate cancer: a nationwide register study.
Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
7. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
9. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
[TBL] [Abstract][Full Text] [Related]
10. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
11. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
12. Fracture risk in patients with prostate cancer on androgen deprivation therapy.
López AM; Pena MA; Hernández R; Val F; Martín B; Riancho JA
Osteoporos Int; 2005 Jun; 16(6):707-11. PubMed ID: 15714259
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
Lee CH; Huang G; Chan PH; Hai J; Yeung CY; Fong CH; Woo YC; Ho KL; Yiu MK; Leung F; Lau TW; Tse HF; Lam KS; Siu CW
PLoS One; 2017; 12(2):e0171495. PubMed ID: 28158241
[TBL] [Abstract][Full Text] [Related]
14. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
16. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
Smith MR; Lee WC; Brandman J; Wang Q; Botteman M; Pashos CL
J Clin Oncol; 2005 Nov; 23(31):7897-903. PubMed ID: 16258089
[TBL] [Abstract][Full Text] [Related]
18. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
[TBL] [Abstract][Full Text] [Related]
20. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
